Literature DB >> 1567623

The pulmonary autograft--a permanent aortic valve.

D Ross1, M Jackson, J Davies.   

Abstract

Between 1969 and 1991, 339 patients had an aortic valve replacement with their own living pulmonary valve at the National Heart Hospital, Guy's Hospital and the Harley Street Clinic, London. The longest follow-up is 24 years and cumulative follow-up is 3774 patient-years. No form of anticoagulation was used and there were no emboli. There were 25 hospital deaths (7.4%) but only 1 death since 1976. Late deaths occurred in 38 patients mainly from technical mal-insertion. Bacterial endocarditis occurred in 11 patients. Thirty-eight patients were re-operated upon and account for 15 of the late deaths. Freedom from re-operation was 85% and the actuarial patient survival was 80% at 20 years. There has been no evidence of primary tissue degeneration and explanted valves showed normal cusp cellularity. Accumulating evidence suggests that the cusps not only survive permanently but can grow with the patient making the operation ideal for children.

Entities:  

Mesh:

Year:  1992        PMID: 1567623     DOI: 10.1016/1010-7940(92)90115-e

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Congenital Valvar Aortic Stenosis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-12

2.  The Ross procedure in children: a systematic review.

Authors:  Morgan K Moroi; Emile A Bacha; David M Kalfa
Journal:  Ann Cardiothorac Surg       Date:  2021-07

3.  Ross operation using a bovine bioprosthetic valve with autologous pericardial conduit in the pulmonary position.

Authors:  M S Urrea; V Herrera; A Rey; J Vargas
Journal:  Tex Heart Inst J       Date:  1993

4.  Age-Dependent Changes in Geometry, Tissue Composition and Mechanical Properties of Fetal to Adult Cryopreserved Human Heart Valves.

Authors:  Daphne van Geemen; Ana L F Soares; Pim J A Oomen; Anita Driessen-Mol; Marloes W J T Janssen-van den Broek; Antoon J van den Bogaerdt; Ad J J C Bogers; Marie-José T H Goumans; Frank P T Baaijens; Carlijn V C Bouten
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.